Claims
- 1. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide encoding the polypeptide comprising amino acid 1 to amino acid 118 as set forth in SEQ ID NO:2; (b) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a) or (b); and (c) a polynucleotide fragment of the polynucleotide of (a) or (b).
- 2. The polynucleotide of claim 1 wherein the polynucleotide is DNA.
- 3. The polynucleotide of claim 2 which encodes the polypeptide comprising amino acid 1 to 118 of SEQ ID NO:2.
- 4. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide which encodes a mature polypeptide having the amino acid sequence expressed by the DNA contained in ATCC Deposit No. 75712; (b) a polynucleotide which encodes a polypeptide having the amino acid sequence expressed by the DNA contained in ATCC Deposit No. 75712; (c) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a); and, (d) a polynucleotide fragment of the polynucleotide of (a), (b) or (c).
- 5. The polynucleotide of claim 1 comprising the sequence as set forth in SEQ ID No. 1 from nucleotide 1 to nucleotide 357.
- 6. A vector containing the DNA of claim 2.
- 7. A host cell genetically engineered with the vector of claim 6.
- 8. A process for producing a polypeptide comprising expressing from the host cell of claim 7 the polypeptide encoded by said DNA.
- 9. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of claim 6.
- 10. A polypeptide selected from the group consisting of:
(a) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof; and (b) a polypeptide encoded by the cDNA of ATCC Deposit No. 75712 and fragments, analogs and derivatives of said polypeptide.
- 11. The polypeptide of claim 9 wherein the polypeptide comprises amino acid 1 to amino acid 118 of SEQ ID NO:2.
- 12. A compound which inhibits the polypeptide of claim 10.
- 13. A method for the treatment of a patient having need of MIF-3 comprising administering to the patient a therapeutically effective amount of the polypeptide of claim 10.
- 14. The method of claim 13 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
- 15. A method for the treatment of a patient having need to inhibit MIF-3 polypeptide comprising administering to the patient a therapeutically effective amount of the compound of claim 12.
- 16. A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of claim 11 comprising determining a mutation in a nucleic acid sequence encoding said polypeptide.
- 17. A diagnostic process comprising analyzing for the presence of the polypeptide of claim 10 in a sample derived from a host.
- 18. A method for identifying compounds which bind to and inhibit activation of the polypeptide of claim 11 comprising:
(a) contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound under conditions to permit binding to the receptor; and (b) determining whether the compound binds to and inhibits the receptor by detecting the absence of a signal generated from the interaction of the compound with the receptor.
Parent Case Info
[0001] This application is a Continuation of and claims priority under 35 U.S.C. §120 to patent application Ser. No. 09/286,290, filed Apr. 6, 1999, which is a Divisional of and claims priority under 35 U.S.C. §120 to patent application Ser. No. 08/903,224, filed Jul. 22, 1997 (issued as U.S. Pat. No. 5,986,060) which claims priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 08/460,528, filed Jun. 2, 1995 (issued U.S. Pat. No. 5,650,295) which is a continuation-in-part of, and claims priority under 35 U.S.C. §120 to, U.S. Patent Application No. PCT/US94/05385, filed May 16, 1994. Each of the above referenced patents and patent applications are herein incorporated by reference in the entirety.
Divisions (2)
|
Number |
Date |
Country |
Parent |
08903224 |
Jul 1997 |
US |
Child |
09286290 |
Apr 1999 |
US |
Parent |
08460528 |
Jun 1995 |
US |
Child |
08903224 |
Jul 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09286290 |
Apr 1999 |
US |
Child |
10178731 |
Jun 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US94/05385 |
May 1994 |
US |
Child |
08460528 |
Jun 1995 |
US |